Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 179 Published: July 29, 2022 Report Code: GDGMDHC22238IDB

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2022, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 12, 8, 1, 51, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 6, 1 and 1 molecules, respectively.

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).

– The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) (Toxicology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

9 Meters Biopharma Inc
Advanced Innovative Partners Inc
Advenchen Laboratories LLC
Aileron Therapeutics Inc
Allander Biotechnologies LLC
Amryt Pharma Plc
Aqualung Therapeutics Corp
BCN Biosciences LLC
BioCurity Pharmaceuticals Inc
BioIncept LLC
Bolder Biotechnology Inc
Cellphire Inc
Ceramedix Holding LLC
Ceramide Therapeutics LLC
Chrysalis BioTherapeutics Inc
Clevexel Pharma SA
Connext Co Ltd
Consegna Pharma Inc
Creative Medical Technology Holdings Inc
Devonian Health Group Inc
Enveric Biosciences Inc
Enzychem Lifesciences Corp
EpicentRx Inc
Exponential Biotherapies Inc
Extend Biosciences Inc
Fibroplate Inc
Foresee Pharmaceuticals Co Ltd
Genexine Inc
Genome Protection Inc
GNI Group Ltd
Humanetics Corp
iNtRON Biotechnology Inc
KBP Biosciences Co Ltd
Lutris Pharma
Luxena Pharmaceuticals Inc
Matrix Biomed Inc
Meabco AS
Medesis Pharma SA
Neumedicines Inc
Neuropathix Inc
New Amsterdam Sciences Inc
Novartis AG
Noveome Biotherapeutics Inc
Onconova Therapeutics Inc
Original BioMedicals Co Ltd
Oxacell AG
P2D Inc
Partner Therapeutics Inc
Perpetuum BV
PharmaIN Corp
Phoenicia Biosciences Inc
Pluristem Therapeutics Inc
Regeneus Ltd
RepoCeuticals ApS
RxBio Inc
Soligenix Inc
Statera Biopharma Inc
Sunny Pharmtech Inc
Synedgen Inc
TheraSource LLC
Tonix Pharmaceuticals Holding Corp
Valenta Pharm
VasoDynamics Ltd
Vera Salus Ricerca Srl
Worphmed Srl
Xequel Bio Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Overview

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Companies Involved in Therapeutics Development

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drug Profiles

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Discontinued Products

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Product Development Milestones

Featured News & Press Releases

Oct 19, 2022: Enzychem Lifesciences announces poster presentation of EC-18 at the Radiation Research Society 2022 annual meeting

Oct 19, 2022: Enzychem Lifesciences announces poster presentation of EC-18 at the Radiation Research Society 2022 annual meeting

Jul 21, 2022: Eckert & Ziegler Affiliate receives further NIAID funding for clinical development

Apr 26, 2022: New studies published comparing BIO 300 to Neulasta for acute radiation syndrome

Mar 24, 2022: Tanner Pharma increases Europe-based inventory of Leukine to expand availability and enhance response to potential radiation exposure due to the ongoing Conflict in Ukraine

Dec 01, 2021: Statera Biopharma announces FDA lifts clinical hold on entolimod

Nov 18, 2021: Enveric Biosciences announces positive preclinical data for EV102 Radiodermatitis Drug Candidate

Sep 22, 2021: Humanetics announces results from phase 1 trial of BIO 300 oral powder

Jul 20, 2021: Neuropathix announces publication of PCT patent application for the treatment of radiation dermatitis and other skin disorders

Jun 08, 2021: Affiliate receives additional NIAID funding to advance pharmaceutical development

Feb 18, 2021: Partner Therapeutics announces publication of two studies demonstrating Leukine improves survival in Acute Radiation Syndrome (ARS)

Feb 08, 2021: Enzychem Lifesciences announces poster presentation at AACR Virtual Annual Meeting 2021

Jan 26, 2021: Enzychem Lifesciences receives NASA grant funding to evaluate EC-18 as a protective agent for radiation and pathogen-induced tissue damage and inflammation in space

Oct 20, 2020: Humanetics presents at the Annual Radiation Research Society meeting

Oct 15, 2020: Meabco's drug candidate efficiently mitigates radiation-induced gastrointestinal syndrome in mice

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Dormant Projects, 2022

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.